Quinazolinone Compounds Targeting IKZF1 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers involving deregulated transcription factors like IKZF1 and IKZF3 lack effective targeting mechanisms, particularly in modulating ubiquitin E3 ligase activity to degrade these proteins.
Innovation Solution
Development of substituted quinazolinone compounds that bind to cereblon, modulating the ubiquitin E3 ligase activity to specifically target IKZF1 and/or IKZF3 for degradation, thereby treating cancers mediated by these transcription factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional cancer treatments are used, then general anti-cancer effects are achieved, but specific targeting of IKZF1 and IKZF3 transcription factors is lacking
Solution Approach 1:
The patent introduces cereblon (CRBN) as an intermediary target. The quinazolinone compounds do not directly degrade IKZF1/3 but bind to CRBN, which then mediates the ubiquitination and degradation of IKZF1/3 through the E3 ligase complex. This intermediary mechanism enables specific targeting of the transcription factors while maintaining treatment reliability.
Solution Approach 2:
The patent modifies the substrate specificity parameter of the E3 ligase system by using small molecule ligands (thalidomide, lenalidomide, and quinazolinone compounds) that bind to CRBN and alter its conformational state. This parameter change redirects the ubiquitination activity from normal substrates to IKZF1/3 transcription factors, achieving precise targeting.
2Reliability
If E3 ligase activity is modulated to degrade IKZF1 and IKZF3, then targeted cancer treatment is achieved, but complexity of the molecular mechanism increases
Solution Approach 1:
The patent utilizes the existing CRBN-E3 ligase complex as an intermediary system. Rather than creating a completely new degradation mechanism, the invention hijacks the natural ubiquitin-proteasome system through CRBN, which serves as the intermediary between the small molecule drug and the IKZF1/3 targets. This reduces the apparent complexity by leveraging existing cellular machinery.
Solution Approach 2:
The patent exploits the universal nature of the CRBN-E3 ligase complex, which normally functions in diverse biological processes. By binding to CRBN, a single class of compounds (quinazolinones) can modulate this universal system to achieve multiple therapeutic effects including degradation of various Ikaros family transcription factors, making the mechanism broadly applicable despite its complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively degrade IKZF1 and/or IKZF3 transcription factors, providing a therapeutic approach for cancers where these factors are involved in pathogenesis, offering a targeted mechanism for cancer treatment.
Implementation Method 1
Ubiquitin-mediated proteolysis begins with ligation of one or more ubiquitin molecules to a particular protein substrate. Ubiquitination occurs through the activity of ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin-protein ligases (E3), acting sequentially to attach ubiquitin to lysine residues of substrate proteins.
Implementation Method 2
Each targets a specific substrate for ubiquitination and subsequent degradation by the proteosome.
Data Source
AI summary
Disclosed are substituted quinazolinone compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions to treat diseases, disorders, or conditions such as those relating to unregulated protein function and/or levels.